## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG 1.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($743.25)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026**
- Source: The Manila Times | 20260102T211735 | Neutral | Relevance: 100%
- Regeneron Pharmaceuticals, Inc. announced it will release its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before market open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss these results.

**2. Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week**
- Source: MSN | 20260103T000842 | Bearish | Relevance: 100%
- This article is a placeholder with no actual content to summarize. It indicates that Regeneron Pharmaceuticals, Inc. (REGN) crashed last week but provides no details on why or what the impact was.

**3. Generate Investment Management Ltd Acquires 6,778 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251231T114510 | Bullish | Relevance: 100%
- Generate Investment Management Ltd significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 56.5% during the third quarter, purchasing an additional 6,778 shares, bringing its total holdings to 18,778 shares valued at approximately $10.56 million. Other institutional investors also made substantial moves in REGN stock, with Dodge & Cox increasing its holdings by 64.6% and Norges Bank acquiring a new position worth about $628 million. Analysts maintain a "Moderate Buy" rating for Regeneron, with an average price target of $779.45.

**4. Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026**
- Source: Quiver Quantitative | 20260102T211635 | Somewhat-Bullish | Relevance: 98%
- Regeneron Pharmaceuticals will release its Q4 and full year 2025 financial and operational results on January 30, 2026, before U.S. markets open, followed by a conference call and webcast at 8:30 AM Eastern Time. The company, known for developing life-transforming medicines, will provide insights into its performance, leveraging its proprietary technologies and genetics center. A replay and transcript of the call will be available online for 30 days.

**5. Why Is Outlook Therapeutics Stock Sinking Friday? - Outlook Therapeutics (NASDAQ:OTLK)**
- Source: Benzinga | 20260102T130904 | Somewhat-Bearish | Relevance: 74%
- Outlook Therapeutics' stock plummeted after the FDA again rejected its Lytenava filing for wet AMD, citing insufficient evidence despite a prior resubmission. This marks the second time the FDA has issued a complete response letter for the drug, pushing the stock to a new 52-week low. The company is now exploring alternative pathways for approval in the U.S. and other markets.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.55 elevated, pricing in significant growth expectations. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +12%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $82.3B |
| Beta | 0.37 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.55 |
| Forward P/E | 20.0 |
| Current P/E | 18.0 |
| YoY Growth | -10.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at 0.8% (minimal 5-day change). Below STRENGTH zone by 2.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.36), momentum weakening. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.80% (CS: 52) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | -1.36 | Bearish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 1.091x | Above |
| vs SMA200 | 1.285x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $776.31
- **Stop Loss:** $743.25 (4.3% risk)
- **Target:** $809.37 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 43
- **Position Value:** $33,381.33
- **Portfolio %:** 33.38%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*